asa guidelines on glp 1 2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations the peri-procedural use of GLP-1/GIP receptor agonists Glucagon-Like Peptide 1 Receptor Agonists

Cachexia is a significant loss of body weight, mainly from muscle mass, that induces a loss of physical function and cannot be reversed by conventional nutritional means (69)

Most clinical trial data supports use of 3 to 6 months without long-term safety concerns

Additionally, by slowing gastric emptying, it increases feelings of fullness

Maintenance microdosing Instead of stopping completely, some people transition to a very low maintenance dose

This approach helps reduce side effects, improve adherence, and drastically lower pharmacy costs all without compromising outcomes

GLP-1 medications also improve cardiovascular outcomes and reduce type 2 diabetes risk, offering benefits beyond weight reduction